InsiderTrades.com logo
Stephen P. Carey net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Stephen Carey Biography and Net Worth

Senior Vice President, Finance and Chief Financial Officer of ANI Pharmaceuticals

Mr. Carey is ANI’s Senior Vice President, Finance and Chief Executive Officer, and has over 30 years of experience as a financial executive, more than 25 of which are in the pharmaceutical industry. Prior to joining ANI in May 2016, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc. (“Par”) from June 2007 to October 2015, including Senior Vice President, Controller and Principal Accounting Officer. During his tenure at Par, he supported the company during its 2012 $1.9 billion leveraged buyout with TPG Capital and ultimately, its sale to Endo International plc in 2015 for $8 billion. Prior to that, Mr. Carey held various financial and accounting positions at Schering-Plough Corporation in support of its U.S. and European branded pharmaceutical businesses. Mr. Carey began his career at PricewaterhouseCoopers and graduated from Montclair State University with a B.S. in Accounting.

What is Stephen P. Carey's net worth?

The estimated net worth of Stephen P. Carey is at least $10.44 million as of December 17th, 2024. Mr. Carey owns 154,468 shares of ANI Pharmaceuticals stock worth more than $10,443,581 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Carey may own. Additionally, Mr. Carey receives a salary of $1,110,000.00 as Senior Vice President, Finance and Chief Financial Officer at ANI Pharmaceuticals. Learn More about Stephen P. Carey's net worth.

How old is Stephen P. Carey?

Mr. Carey is currently 53 years old. There are 8 older executives and no younger executives at ANI Pharmaceuticals. The oldest executive at ANI Pharmaceuticals is Mr. James G. Marken, Senior Vice President of Operations, who is 61 years old. Learn More on Stephen P. Carey's age.

What is Stephen P. Carey's salary?

As the Senior Vice President, Finance and Chief Financial Officer of ANI Pharmaceuticals, Inc., Mr. Carey earns $1,110,000.00 per year. The highest earning executive at ANI Pharmaceuticals is Mr. Nikhil Lalwani, President, CEO & Director, who commands a salary of $2,320,000.00 per year. Learn More on Stephen P. Carey's salary.

How do I contact Stephen P. Carey?

The corporate mailing address for Mr. Carey and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at ir@anipharmaceuticals.com. Learn More on Stephen P. Carey's contact information.

Has Stephen P. Carey been buying or selling shares of ANI Pharmaceuticals?

Stephen P. Carey has not been actively trading shares of ANI Pharmaceuticals within the last three months. Most recently, Stephen P. Carey sold 7,500 shares of the business's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a transaction totalling $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at $8,617,769.72. Learn More on Stephen P. Carey's trading history.

Who are ANI Pharmaceuticals' active insiders?

ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.

Are insiders buying or selling shares of ANI Pharmaceuticals?

During the last year, insiders at the specialty pharmaceutical company sold shares 33 times. They sold a total of 268,126 shares worth more than $16,946,714.15. The most recent insider tranaction occured on March, 13th when VP Meredith Cook sold 400 shares worth more than $25,332.00. Insiders at ANI Pharmaceuticals own 12.7% of the company. Learn More about insider trades at ANI Pharmaceuticals.

Information on this page was last updated on 3/13/2025.

Stephen P. Carey Insider Trading History at ANI Pharmaceuticals

See Full Table

Stephen P. Carey Buying and Selling Activity at ANI Pharmaceuticals

This chart shows Stephen P Carey's buying and selling at ANI Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals logo
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Read More

Today's Range

Now: $67.61
Low: $67.02
High: $68.49

50 Day Range

MA: $60.49
Low: $54.51
High: $68.36

2 Week Range

Now: $67.61
Low: $52.50
High: $70.00

Volume

355,964 shs

Average Volume

256,304 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63